{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T21:23:39Z","timestamp":1787261019868,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["SEBCATP-2022\/100004"],"award-info":[{"award-number":["SEBCATP-2022\/100004"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ctro.2026.101232","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T23:32:32Z","timestamp":1783726352000},"page":"101232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world outcomes of stage III non-small cell lung cancer in the durvalumab era: insights from a socioeconomically deprived population"],"prefix":"10.1016","volume":"60","author":[{"given":"Adam L.","family":"Peters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrison Douglas","family":"Stubbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean F.","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"McGarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina","family":"Tsim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Lumsden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Stares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Y.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin G.","family":"Blyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Maclay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2026.101232_bb0005","series-title":"Five-year survival outcomes from the pacific trial: durvalumab after chemoradiotherapy in Stage III non\u2013small-cell lung cancer","first-page":"1301","author":"Spigel","year":"2022"},{"issue":"12","key":"10.1016\/j.ctro.2026.101232_bb0010","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jtho.2022.07.1148","article-title":"Durvalumab after sequential chemoradiotherapy in stage III, unresectable NSCLC: the phase 2 PACIFIC-6 trial","volume":"17","author":"Garassino","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctro.2026.101232_bb0015","article-title":"142P CODAK real-world study: interim analysis of clinical outcomes in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (CRT) in the United Kingdom","volume":"16","author":"Franks","year":"2022","journal-title":"Immuno-Oncol Technol"},{"issue":"Suppl. 1","key":"10.1016\/j.ctro.2026.101232_bb0020","first-page":"S31","article-title":"The STROBE guidelines","volume":"13","author":"S","year":"2019","journal-title":"Saudi J Anaesth"},{"issue":"7","key":"10.1016\/j.ctro.2026.101232_bb0025","doi-asserted-by":"crossref","first-page":"709","DOI":"10.21037\/qims.2018.08.02","article-title":"The 8th lung cancer TNM classification and clinical staging system: review of the changes and clinical implications","volume":"8","author":"Lim","year":"2018","journal-title":"Quant Imaging Med Surg"},{"key":"10.1016\/j.ctro.2026.101232_bb0030","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the eastern cooperative oncology group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ctro.2026.101232_bb0035","series-title":"Treatment patterns for patients with Unresected stage III NSCLC: analysis of the surveillance, epidemiology, and end results (SEER) database","author":"Shang","year":"2022"},{"key":"10.1016\/j.ctro.2026.101232_bb0040","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41416-020-01069-z","article-title":"The current treatment landscape in the UK for stage III NSCLC","volume":"123","author":"Evison","year":"2020","journal-title":"Br J Cancer"},{"issue":"20","key":"10.1016\/j.ctro.2026.101232_bb0045","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after Chemoradiotherapy in stage III non\u2013small-cell lung Cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ctro.2026.101232_bb0050","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/bjc.2014.108","article-title":"The impact of socioeconomic status on access to cancer clinical trials","volume":"111","author":"Sharrocks","year":"2014","journal-title":"Br J Cancer"},{"issue":"19","key":"10.1016\/j.ctro.2026.101232_bb0055","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/jnci\/djr325","article-title":"Sequential vs concurrent chemoradiation for stage III non\u2013small cell lung cancer: randomized phase III trial RTOG 9410","volume":"103","author":"Curran","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.ctro.2026.101232_bb0060","article-title":"Concurrent chemoradiotherapy in non-small cell lung cancer","author":"O\u2019Rourke","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.ctro.2026.101232_bb0065","doi-asserted-by":"crossref","DOI":"10.1186\/s12938-025-01390-9","article-title":"Concurrent vs. sequential chemoradiotherapy: a survival boost for lung cancer patients","volume":"24","author":"Xu","year":"2025","journal-title":"Biomed Eng Online"},{"key":"10.1016\/j.ctro.2026.101232_bb0070","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","article-title":"Meta-analysis of concomitant versus sequential Radiochemotherapy in locally advanced non\u2013small-cell lung Cancer","volume":"28","author":"Aup\u00e9rin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2026.101232_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108576","article-title":"Real-world outcomes of subsequent treatment strategies after durvalumab consolidation in stage III unresectable non-small cell lung cancer","volume":"204","author":"Crespi","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctro.2026.101232_bb0080","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.lungcan.2020.10.006","article-title":"Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): real-world data on survival and safety from the German expanded-access program (EAP)","volume":"150","author":"Faehling","year":"2020","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.ctro.2026.101232_bb0085","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s10637-021-01091-9","article-title":"Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients","volume":"39","author":"Taugner","year":"2021","journal-title":"Investig New Drugs"},{"issue":"2","key":"10.1016\/j.ctro.2026.101232_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2024.11.002","article-title":"Outcomes Following Treatment for Progression in Patients Treated With Durvalumab Consolidation in LA-NSCLC","volume":"26","author":"Stalker","year":"2025","journal-title":"Clinical Lung Cancer."},{"key":"10.1016\/j.ctro.2026.101232_bb0095","first-page":"61","article-title":"CONCORDE: a phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer","volume":"25","author":"Walls","year":"2020","journal-title":"Clin Transl Rad Oncol"},{"key":"10.1016\/j.ctro.2026.101232_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113373","article-title":"A phase 2 trial of durvalumab treatment following radiation monotherapy in patients with non-small cell lung cancer ineligible for stage III chemoradiotherapy: the SPIRAL-RT study","volume":"195","author":"Yamada","year":"2023","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ctro.2026.101232_bb0105","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ijc.34963","article-title":"The use of pembrolizumab monotherapy for the management of head and neck squamous cell carcinoma (HNSCC) in the UK","volume":"155","author":"Vasiliadou","year":"2024","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.ctro.2026.101232_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16040709","article-title":"Reasons for treatment discontinuation and their effect on outcomes of immunotherapy in Southwest Finland: a retrospective, real-world cohort study","volume":"16","author":"Virtanen","year":"2024","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.ctro.2026.101232_bb0115","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.clon.2024.02.004","article-title":"The UK divide: does having a pembrolizumab\u2013chemotherapy option in head and neck cancer matter? Real-world experience of first-line palliative pembrolizumab monotherapy and pembrolizumab\u2013chemotherapy combination in Scotland","volume":"36","author":"Thapa","year":"2024","journal-title":"Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2026.101232_bb0120","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-021-03008-9","article-title":"Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators","volume":"19","author":"Stellato","year":"2021","journal-title":"J Transl Med"},{"issue":"30","key":"10.1016\/j.ctro.2026.101232_bb0125","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1200\/JCO.19.00318","article-title":"Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody","volume":"37","author":"Maher","year":"2019","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ctro.2026.101232_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15235502","article-title":"Immune-related adverse events, biomarkers of systemic inflammation, and survival outcomes in patients receiving Pembrolizumab for non-small-cell lung cancer","volume":"15","author":"Raynes","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ctro.2026.101232_bb0135","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-27960-2","article-title":"Immune-related adverse events and the balancing act of immunotherapy","volume":"13","author":"Conroy","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctro.2026.101232_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108572","article-title":"Feasibility, acceptability and clinical outcomes of a real-world, regional lung cancer prehabilitation programme for patients undergoing curative intent radiotherapy","volume":"204","author":"Gourlay","year":"2025","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.ctro.2026.101232_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2023.101698","article-title":"Implementation of a geriatric oncology service at the Royal Marsden Hospital","volume":"15","author":"Mac Eochagain","year":"2024","journal-title":"J Geriatr Oncol"},{"issue":"20","key":"10.1016\/j.ctro.2026.101232_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17203329","article-title":"Multidisciplinary prehabilitation reduces hospitalization time and suggests improved survival in patients with radiologically diagnosed lung cancer","volume":"17","author":"Phillips","year":"2025","journal-title":"Cancers"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826001278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826001278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T20:24:59Z","timestamp":1787257499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630826001278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":30,"alternative-id":["S2405630826001278"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101232","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world outcomes of stage III non-small cell lung cancer in the durvalumab era: insights from a socioeconomically deprived population","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101232","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101232"}}